Chronic Pain Clinical Trial
— BETTEROfficial title:
Reducing the Transition From Acute to Chronic Musculoskeletal Pain Among Older Adults
Verified date | August 2023 |
Source | University of North Carolina, Chapel Hill |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The investigators have developed a three component intervention to support shared decision-making during the early recovery phase for older adults who present to the emergency department (ED) or orthopedic urgent care with acute musculoskeletal pain. The first component is a brief interactive video to enhance patient knowledge and self-efficacy regarding treatment options with the intent of facilitating conversations between patients and emergency providers. The second component is a protocol-guided phone conversation (telecare) between a nurse care manager and the patient at 48-72 hours following discharge to assess pain severity and interference with daily activities, review analgesic use and side effects and recovery-promoting behaviors, and discuss adjustments to the patients treatment. The third component is communication with the patient's primary care provider following the telecare call to inform them of the patient's condition and treatment plan and encourage primary care followup. The short-term objective of this project is to test the efficacy of this intervention to reduce the transition from acute to chronic musculoskeletal pain among older adults and obtain data to inform implementation. The investigators will conduct a three-arm randomized controlled trial with adults aged 50 years and older who present to the ED or orthopedic urgent care with acute musculoskeletal pain. Patients will be randomized to (1) the full intervention (video + telecare + communication with primary provider), (2) video alone, or (3) usual care. The primary outcome will be pain, measured longitudinally over the course of the year following the acute care visit. Secondary outcomes will include physical function, analgesic side effects and adverse events, opioid use, depression and anxiety symptoms, sleep duration and quality, and healthcare utilization at one, three, six, and twelve months. Secondary analyses will (1) examine whether the intervention has its effect by promoting shared decision-making, and (2) estimate the cost-effectiveness of the intervention. The long-term goal of this work is to develop, test, and implement interventions that improve long-term health outcomes for older adults with acute musculoskeletal pain.
Status | Completed |
Enrollment | 330 |
Est. completion date | June 22, 2023 |
Est. primary completion date | December 27, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years and older |
Eligibility | Inclusion Criteria: - Age 50 years and older - Present to UNC ED patient with primary complaint of acute musculoskeletal pain - Average pain score >/= 4 on 0-10 scale - Expected discharge from the ED Exclusion Criteria: - patient does not speak English - primary pain located in the head, chest, or abdomen - pain due to ischemia, infection, or some other cause not due to MSP (blood clot, kidney stone, etc.) - primary pain due to self-injury - patient is critically ill determined by an acuity score of 1 in the tracking board - diagnosis of somatoform disorder, schizophrenia, dementia, or bipolar disorder - patient is a prisoner or in police custody - self-reported daily opioid use for more than 2 weeks - resides in a nursing home or is homeless - at-risk alcohol use - speech, hearing, vision problems - cognitively impaired (6-item Brief Screener) - nonworking phone number (follow-up occurs via phone calls) |
Country | Name | City | State |
---|---|---|---|
United States | University of North Carolina Hospitals | Chapel Hill | North Carolina |
Lead Sponsor | Collaborator |
---|---|
University of North Carolina, Chapel Hill | Duke University, Elon University, Indiana University, National Institute on Aging (NIA), Yale University |
United States,
Gan TJ, Joshi GP, Zhao SZ, Hanna DB, Cheung RY, Chen C. Presurgical intravenous parecoxib sodium and follow-up oral valdecoxib for pain management after laparoscopic cholecystectomy surgery reduces opioid requirements and opioid-related adverse effects. Acta Anaesthesiol Scand. 2004 Oct;48(9):1194-207. doi: 10.1111/j.1399-6576.2004.00495.x. — View Citation
Hurka-Richardson K, Platts-Mills TF, McLean SA, Weinberger M, Stearns SC, Bush M, Quackenbush E, Chari S, Aylward A, Kroenke K, Kerns RD, Weaver MA, Keefe FJ, Berkoff D, Meyer ML. Brief Educational Video plus Telecare to Enhance Recovery for Older Emergency Department Patients with Acute Musculoskeletal Pain: an update to the study protocol for a randomized controlled trial. Trials. 2022 May 12;23(1):400. doi: 10.1186/s13063-022-06310-z. — View Citation
Platts-Mills TF, Hollowell AG, Burke GF, Zimmerman S, Dayaa JA, Quigley BR, Bush M, Weinberger M, Weaver MA. Randomized controlled pilot study of an educational video plus telecare for the early outpatient management of musculoskeletal pain among older emergency department patients. Trials. 2018 Jan 5;19(1):10. doi: 10.1186/s13063-017-2403-8. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean Brief Pain Inventory-Short Form (BPI-SF) Combined Pain Severity and Interference Score | The Brief Pain Inventory-Short Form (BPI-SF) is an 11-item measure of pain severity and pain interference. Patients will rate their pain severity and interference over the past week on a 0-10 numeric scale at 3 discrete time periods (1, 3, and 6 months). End points for the severity items include 0 which equals "no pain" and 10 which equals "pain as bad as you can imagine." End points for the interference items include 0 which equals "does not interfere" and 10 "completely interferes." Higher scores reflect more pain severity and more pain interference. A composite score will be calculated by averaging scores from both the pain severity and interference items (all 11-items). Results from the 3 time periods will be analyzed longitudinally. | Month 1 (following ED or orthopedic urgent care visit) to Month 6 | |
Secondary | Mean Pain Severity on the Brief Pain Inventory-Short Form (BPI-SF) Score | The BPI-SF is an 11-item measure of pain severity and pain interference with severity entailing 4 of the questions. Patient's will rate their pain severity over the past week on a 0-10 numeric rating scale, with a higher score reflecting more pain. End points include 0 which equals "no pain" and 10 which equals "pain as bad as you can imagine." Answers to each of the 4 questions will be reported as mean values for each time point (Month 1, 3, and 6). | Up to 6 months | |
Secondary | Mean Pain Interference on the BPI-SF Score | The BPI-SF is an 11-item measure of pain severity and pain interference with interference with daily activities entailing 7 of the questions. Patient's will rate their pain interference over the past week, on a 0-10 scale with a higher score reflecting more interference with activities. End points include 0 which equals "does not interfere" and 10 which equals "completely interferes." Answers to each of the 7 questions will be reported as mean values for each time point (Month 1, 3, and 6). | Up to 6 months | |
Secondary | Mean Symptom Distress Score | The Opioid-Related Symptom Distress Scale (OR-SDS) will be used to assess subject-reported levels of frequency and severity of 10 symptoms known to be associated with opioid medication usage, such as drowsiness, dizziness, and constipation. Added to this measure are 5 other symptoms (including shortness of breath, falls, abdominal pain, bloody stool, and 'other'), reflecting side effects for patients taking NSAIDs or acetaminophen. Symptom frequency will be rated as: 1=rarely, 2=occasionally, 3=frequently, or 4=almost constantly, with higher ratings indicating more frequent symptoms (ranging from 1 to 4). Symptom severity will be rated as: 1=slightly, 2-moderate, 3=severe, or 4=very severe, with higher ratings indicating more severe symptoms (ranging from 1 to 4). Patients who deny a symptom will be given a score of zero for frequency and severity. A mean symptom distress score was calculated for each arm based on patient reported scores for severity and frequency. | 1 week & 1 month | |
Secondary | Percent of Participants With Opioid Use During the Past Week | Patients will be asked if they have used opioids during the past week at each of the follow-up time points. This will be a dichotomous outcome in which 'yes' will indicate opioid use in the past week and 'no' will indicate no opioid use in the past week. | 1, 3, 6, and 12 months | |
Secondary | PROMIS Measure: Mean T-score Physical Function-4 | Patient report of physical function will be measured using the Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function-4 for chores, ability to use stairs, walking, and running errands on a 5-point scale with end points of "without any difficulty" and "unable to do." Higher scores reflect less difficulty. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. Therefore a person with a T-score of 40 is one SD below the mean. These values will be compared to the value obtained from the baseline assessment with patients reporting their function prior to injury. The data will be analyzed longitudinally for months 1, 3, 6, and 12 (following the approach for BPI for the primary outcome). | 1, 3, 6, and 12 months | |
Secondary | PROMIS Measure: Mean T-score Global Health-Physical 2a | Patient reported global health will be measured using the PROMIS Global Health-Physical 2a. General physical health is measured on a 5-point scale with end points of "excellent" and "poor," where higher scores reflect better physical health. Ability to carry out every day physical activities is measured on a 5 point scale with end points of "completely" and "not at all," where higher scores reflect better ability. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. Therefore a person with a T-score of 40 is one SD below the mean. These values will be compared to the value obtained from the baseline assessment with patients reporting their global health prior to injury. The data will be analyzed longitudinally for months 1, 3, 6, and 12 (following the approach for BPI for the primary outcome). | 1, 3, 6, and 12 months | |
Secondary | Healthcare Utilization, Mean Days in the Hospital | The number of days the patient spent in the hospital after ED discharge will be collected through patient report and the patient's electronic health record. Analysis will compare these outcomes among study arms. | Up to 12 months | |
Secondary | Healthcare Utilization, Mean Number of Visits to ED/Urgent Care | The number of visits to an ED or urgent care will be collected through patient report and the patient's electronic health record. Analysis will compare these outcomes among study arms. | Up to 12 months | |
Secondary | Healthcare Utilization, Mean Number of Visits to Primary Care Provider | The number of visits to a primary care provider's office will be collected through patient report and the patient's electronic health record. Analysis will compare these outcomes among study arms. | Up to 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01659073 -
Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation
|
N/A | |
Recruiting |
NCT05914311 -
Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration
|
N/A | |
Recruiting |
NCT05422456 -
The Turkish Version of Functional Disability Inventory
|
||
Enrolling by invitation |
NCT05422443 -
The Turkish Version of Pain Coping Questionnaire
|
||
Completed |
NCT05057988 -
Virtual Empowered Relief for Chronic Pain
|
N/A | |
Completed |
NCT04385030 -
Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury
|
N/A | |
Recruiting |
NCT06206252 -
Can Medical Cannabis Affect Opioid Use?
|
||
Completed |
NCT05103319 -
Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
|
||
Completed |
NCT03687762 -
Back on Track to Healthy Living Study
|
N/A | |
Completed |
NCT04171336 -
Animal-assisted Therapy for Children and Adolescents With Chronic Pain
|
N/A | |
Completed |
NCT03179475 -
Targin® for Chronic Pain Management in Patients With Spinal Cord Injury
|
Phase 4 | |
Completed |
NCT03418129 -
Neuromodulatory Treatments for Pain Management in TBI
|
N/A | |
Completed |
NCT03268551 -
MEMO-Medical Marijuana and Opioids Study
|
||
Recruiting |
NCT06060028 -
The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain
|
N/A | |
Recruiting |
NCT06204627 -
TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain
|
N/A | |
Completed |
NCT05496205 -
A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00983385 -
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics
|
Phase 3 | |
Recruiting |
NCT05118204 -
Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization
|
Phase 4 | |
Terminated |
NCT03538444 -
Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder
|
N/A | |
Not yet recruiting |
NCT05812703 -
Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain
|